OTCMKTS:STDAF - Stada Arzneimittel Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$102.35 0.00 (0.00 %)
(As of 05/25/2018 04:38 AM ET)
Previous Close$102.35
Today's Range$102.35 - $102.35
52-Week Range$64.91 - $108.40
VolumeN/A
Average Volume2 shs
Market Capitalization$6.38 billion
P/E Ratio30.28
Dividend YieldN/A
Beta0.89

About Stada Arzneimittel (OTCMKTS:STDAF)

Stada Arzneimittel logoSTADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.

Receive STDAF News and Ratings via Email

Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:STDAF
CUSIPN/A
Phone49-6101-6030

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio30.28
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.61 billion
Price / Sales2.44
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares62,340,000

Stada Arzneimittel (OTCMKTS:STDAF) Frequently Asked Questions

What is Stada Arzneimittel's stock symbol?

Stada Arzneimittel trades on the OTCMKTS under the ticker symbol "STDAF."

How were Stada Arzneimittel's earnings last quarter?

Stada Arzneimittel (OTCMKTS:STDAF) released its quarterly earnings results on Thursday, May, 3rd. The company reported $1.20 earnings per share (EPS) for the quarter. The company had revenue of $685.72 million for the quarter. View Stada Arzneimittel's Earnings History.

When is Stada Arzneimittel's next earnings date?

Stada Arzneimittel is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Stada Arzneimittel.

Who are some of Stada Arzneimittel's key competitors?

Who are Stada Arzneimittel's key executives?

Stada Arzneimittel's management team includes the folowing people:
  • Dr. Claudio Albrecht, Chairman of the Exec. Board & CEO (Age 59)
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)
  • Dr. Barthold Piening, Chief Technical Operations Officer & Member of Exec. Board (Age 60)
  • Ms. Leslie Isabelle Iltgen, VP of Investor Relations
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43)

Has Stada Arzneimittel been receiving favorable news coverage?

News stories about STDAF stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Stada Arzneimittel earned a media sentiment score of 0.09 on Accern's scale. They also assigned news headlines about the company an impact score of 46.62 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Stada Arzneimittel?

Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stada Arzneimittel's stock price today?

One share of STDAF stock can currently be purchased for approximately $102.35.

How big of a company is Stada Arzneimittel?

Stada Arzneimittel has a market capitalization of $6.38 billion and generates $2.61 billion in revenue each year.

How can I contact Stada Arzneimittel?

Stada Arzneimittel's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030.


MarketBeat Community Rating for Stada Arzneimittel (STDAF)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  142
MarketBeat's community ratings are surveys of what our community members think about Stada Arzneimittel and other stocks. Vote "Outperform" if you believe STDAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDAF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Stada Arzneimittel (OTCMKTS:STDAF) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Stada Arzneimittel in the last 12 months. There are currently 2 sell ratings for the stock, resulting in a consensus rating of "Sell."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: SellSellSellSell
Consensus Rating Score: 1.001.001.001.00
Ratings Breakdown: 2 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Stada Arzneimittel (OTCMKTS:STDAF) Consensus Price Target History

Price Target History for Stada Arzneimittel (OTCMKTS:STDAF)

Stada Arzneimittel (OTCMKTS:STDAF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/6/2018DZ BankReiterated RatingSellView Rating Details
1/2/2018Nord/LBReiterated RatingSellView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Stada Arzneimittel (OTCMKTS:STDAF) Earnings History and Estimates Chart

Earnings by Quarter for Stada Arzneimittel (OTCMKTS:STDAF)

Stada Arzneimittel (OTCMKTS STDAF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
5/3/2018Q1 2018$1.20$685.72 millionViewN/AView Earnings Details
3/8/2018Q4 2017$0.95$725.35 millionViewN/AView Earnings Details
8/3/2017Q2 2017$1.07$634.02 millionViewN/AView Earnings Details
5/11/2017Q1 2017$0.92$603.33 millionViewN/AView Earnings Details
3/29/2017Q4 2016$0.60$645.28 millionViewN/AView Earnings Details
11/10/2016Q3 2016$0.79$565.72 millionViewN/AView Earnings Details
8/4/2016Q2 2016$1.02$607.25 millionViewN/AView Earnings Details
5/12/2016Q1 2016$0.71$548.11 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Stada Arzneimittel (OTCMKTS:STDAF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Stada Arzneimittel (OTCMKTS STDAF) Insider Trading and Institutional Ownership History

Insider Trading History for Stada Arzneimittel (OTCMKTS:STDAF)

Stada Arzneimittel (OTCMKTS STDAF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Stada Arzneimittel (OTCMKTS STDAF) News Headlines

Source:
DateHeadline
Financial Review: USANA Health Sciences (USNA) versus Stada Arzneimittel (STDAF)Financial Review: USANA Health Sciences (USNA) versus Stada Arzneimittel (STDAF)
www.americanbankingnews.com - May 22 at 9:14 PM
Financial Analysis: USANA Health Sciences (USNA) vs. Stada Arzneimittel (STDAF)Financial Analysis: USANA Health Sciences (USNA) vs. Stada Arzneimittel (STDAF)
www.americanbankingnews.com - May 11 at 5:24 AM
Contrasting Stada Arzneimittel (STDAF) and ChromaDex (CDXC)Contrasting Stada Arzneimittel (STDAF) and ChromaDex (CDXC)
www.americanbankingnews.com - May 5 at 11:17 PM
ChromaDex (CDXC) & Stada Arzneimittel (STDAF) Head-To-Head SurveyChromaDex (CDXC) & Stada Arzneimittel (STDAF) Head-To-Head Survey
www.americanbankingnews.com - May 5 at 1:41 PM
Stada Arzneimittels (STDAF) CEO Claudio Albrecht on Q1 2018 Results - Earnings Call TranscriptStada Arzneimittel's (STDAF) CEO Claudio Albrecht on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 10:24 AM
Contrasting Foamix Pharmaceuticals (FOMX) and Stada Arzneimittel (STDAF)Contrasting Foamix Pharmaceuticals (FOMX) and Stada Arzneimittel (STDAF)
www.americanbankingnews.com - April 27 at 11:28 AM
Stada Arzneimittel (STDAF) Earns Neutral Rating from DZ BankStada Arzneimittel (STDAF) Earns Neutral Rating from DZ Bank
www.americanbankingnews.com - April 20 at 11:19 AM
In Pharma, If You Cant Join Them, Beat ThemIn Pharma, If You Can't Join Them, Beat Them
finance.yahoo.com - April 17 at 9:52 AM
MediWound (MDWD) and Stada Arzneimittel (STDAF) Head-To-Head ContrastMediWound (MDWD) and Stada Arzneimittel (STDAF) Head-To-Head Contrast
www.americanbankingnews.com - April 9 at 9:22 PM
Stada Arzneimittels (STDAF) "Sell" Rating Reaffirmed at Nord/LBStada Arzneimittel's (STDAF) "Sell" Rating Reaffirmed at Nord/LB
www.americanbankingnews.com - March 31 at 1:34 PM
STADA Arzneimittel Aktiengesellschaft (FRA:SAZ) Investors Are Paying Above The Intrinsic ValueSTADA Arzneimittel Aktiengesellschaft (FRA:SAZ) Investors Are Paying Above The Intrinsic Value
finance.yahoo.com - March 16 at 3:31 PM
Stada Arzneimittels (STDAF) CEO Claudio Albrecht on Q4 2017 Results - Earnings Call TranscriptStada Arzneimittel's (STDAF) CEO Claudio Albrecht on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 3:32 PM
DZ Bank Reiterates Sell Rating for Stada Arzneimittel (STDAF)DZ Bank Reiterates Sell Rating for Stada Arzneimittel (STDAF)
www.americanbankingnews.com - February 6 at 1:56 PM
Stada Names Sandoz Manager as Fifth CEO Since 2016Stada Names Sandoz Manager as Fifth CEO Since 2016
finance.yahoo.com - February 1 at 8:05 AM
DZ Bank Reiterates "Sell" Rating for Stada Arzneimittel (STDAF)DZ Bank Reiterates "Sell" Rating for Stada Arzneimittel (STDAF)
www.americanbankingnews.com - January 1 at 6:20 AM
Nord/LB Reiterates "Sell" Rating for Stada Arzneimittel (STDAF)Nord/LB Reiterates "Sell" Rating for Stada Arzneimittel (STDAF)
www.americanbankingnews.com - December 27 at 8:48 AM
Stada Arzneimittels (STDAF) "Sell" Rating Reaffirmed at DZ BankStada Arzneimittel's (STDAF) "Sell" Rating Reaffirmed at DZ Bank
www.americanbankingnews.com - December 26 at 11:28 AM
STADA Arzneimittel AG :STDAF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017STADA Arzneimittel AG :STDAF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 10:57 AM
STADA Arzneimittel AG is trading above its 50 day moving average : STDAF-US : December 21, 2017STADA Arzneimittel AG is trading above its 50 day moving average : STDAF-US : December 21, 2017
finance.yahoo.com - December 21 at 10:38 AM
Stada Arzneimittel (STDAF) Rating Reiterated by DZ BankStada Arzneimittel (STDAF) Rating Reiterated by DZ Bank
www.americanbankingnews.com - December 20 at 12:08 PM
STADA Arzneimittel AG breached its 50 day moving average in a Bearish Manner : STDAF-US : December 6, 2017STADA Arzneimittel AG breached its 50 day moving average in a Bearish Manner : STDAF-US : December 6, 2017
finance.yahoo.com - December 6 at 11:01 AM

SEC Filings

Stada Arzneimittel (OTCMKTS:STDAF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Stada Arzneimittel (OTCMKTS STDAF) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.